|
Palo Alto, CA, - June 24, 2005 – Telik, Inc. (Nasdaq: TELK) announced that company management will provide corporate updates at the Bear Stearns Biotechnology Conference in Cambridge, MA on Tuesday, June 28, 2005 at 9:30 am EDT, and at the Wachovia Nantucket Equity Conference on Nantucket Island, MA on Wednesday, June 29, 2005 at 9:00 am EDT. A live webcast of the presentation at the Wachovia conference will be available on the Telik website, www.telik.com. An archived webcast will be accessible on the Telik site through July 6, 2005.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working to discover, develop and commercialize novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA™ (TLK286), a tumor-activated small molecule product candidate. TELCYTA is in three Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2005 Press Releases2004
Press Releases
2003
Press ReleasesEvents |
